Compounds for the treatment of inflammatory disorders
AssigneeSchering Corporation
InventorsWensheng Yu, Ling Tong, Lei Chen, Joseph A. Kozlowski, Brian J. Lavey, Neng-Yang Shih, Vincent S. Madison, Guowei Zhou, Peter Orth, Zhuyan Guo, Michael K. C. Wong, De-Yi Yang, Seong Heon Kim, Bandarpalle B. Shankar
Life of this patent
Estimating the term…
Abstract
This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF- or combinations thereof.
Claims10
A method of treating a condition or disease selected from the group consisting of septic shock, sepsis syndrome, post ischaemic reperfusion injury, meningitis, psoriasis, an inflammatory bowel disease rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, adult Still's disease, non-insulin dependent diabetes mellitus, asthma, and chronic obstructive pulmonary disease (COPD) in a subject comprising administering to the subject in need of such treatment a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof;
- wherein the compound is represented by Formula (I):
- and, wherein:
- X is selected from the group consisting of —S—, —C(R4)2— or —N(R4)—;
- T is selected from the group consisting of H (with U and V being absent), alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl, and arylalkyl, said aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl being optionally fused with one or more moieties selected from the group consisting of aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl, wherein each of any of the aforementioned alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl groups of T is unsubstituted or optionally independently substituted with one to four R10 moieties;
- U is selected from the group consisting of a covalent bond, —N(R4)—, —N(R4)C(R4)2—, —N(R4)C(O)—, —O—, —N(R4)S(O)2—, —N(R4)C(O)N(R4)—, and —N(R4)C(S)N(R4)—;
- V is absent or present, and if present V is selected from the group consisting of alkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl, said aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl being optionally fused with one or more moieties selected from the group consisting of aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl, wherein each of any of the aforementioned alkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl is unsubstituted or optionally independently substituted with one to four R10 moieties;
- Y is selected from the group consisting of a covalent bond, —(C(R4)2)n—, —N(R4)—, —C(O)N(R4)—, —N(R4)C(O)—, —N(R4)C(O)N(R4)—, —S(O)2N(R4)—, —N(R4)—S(O)2, —O—, —S—, —C(O)—, —S(O)—, and —S(O)2—;
- Z is selected from the group consisting of a covalent bond. —(C(R4)2)n—, —N(R4)—, —C(O)N(R4)—, —N(R4)C(O)—, —N(R4)C(O)N(R4)—, —S(O)2N(R4)—, —N(R4)—S(O)2—, —O—, —S—, —C(O)—, —S(O)—, and —S(O)2—;
- n is 1 to 3;
- R1 is selected from the group consisting of H, —OR4, halogen, alkyl, fluoroalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and arylalkyl, wherein each of the alkyl, fluoroalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and arylalkyl groups of R1 is unsubstituted or optionally independently substituted with one to four R20 moieties, with the proviso that when Y is present and Y is N, S or O, then R1 is not halogen;
- R2 is selected from the group consisting of H, —OR4, halogen, alkyl, fluoroalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and arylalkyl, wherein each of the alkyl, fluoroalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and arylalkyl groups of R2 is unsubstituted or optionally independently substituted with one to four R20 moieties, with the proviso that when Z is present and Z is N, S or O, then R2 is not halogen;
- each R4 is the same or different and is independently selected from the group consisting of H, alkyl, —CH2C≡CCH3, —CH2C≡CCH2OH, and —CH2-cyclopropyl;
- R10 is selected from the group consisting of —OR4, —N(R4)2, —O(fluoroalkyl), halogen, alkyl, fluoroalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl, wherein each of the alkyl, fluoroalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl groups of R10 is unsubstituted or optionally independently substituted with one to four R30 moieties which can be the same or different, each R30 moiety being independently selected from the group of R30 moieties below;
- R20 is selected from the group consisting of halogen, alkyl, fluoroalkyl;
- and
- R30 is selected from the group consisting of halogen, alkyl, and fluoroalkyl.
Dependencies are inferred from the claim text.